BPRDP 056
Alternative Names: BPRDP-056; T-1201Latest Information Update: 19 Sep 2025
At a glance
- Originator Molecular Targeting Technologies; National Health Research Institutes
 - Developer Taivex Therapeutics
 - Class Amines; Antineoplastics; Camptothecins; Drug conjugates; Indolizines; Pyrans; Quinolines; Small molecules; Zinc compounds
 - Mechanism of Action DNA topoisomerase I inhibitors
 
- 
          
            
              Orphan Drug Status
              No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
 - New Molecular Entity Yes
 
Highest Development Phases
- Phase I Solid tumours
 
Most Recent Events
- 19 Sep 2025 Phase-I clinical development for Solid tumours (Late-stage disease) is underway in Taiwan (IV) (NCT04866641)
 - 28 Feb 2025 Adverse events data from preclinical trials in Solid tumours released by Taivex Therapeutics
 - 28 Feb 2025 Taivex Therapeutics plans a phase II trial for Solid tumours (IV)